Table 3.
Change in time to chemotherapy (TTC) by surgical pathway*
| Surgical pathway | No. (%) | Mean (SD) | ΔTTC (95% CI) |
|---|---|---|---|
| Mastectomy: no reconstruction | 1166 (19) | 11.4 (4.3) | 0.5 (+0.0 to +1.0)† |
| Mastectomy: with reconstruction | 784 (13) | 13.8 (4.6) | 3.0 (+2.5 to +3.6)‡ |
| Needle biopsy: BCS: no re-excision | 1973 (32) | 11.0 (3.9) | Referent |
| Needle biopsy: BCS: BCS re-excision | 550 (9) | 13.1 (4.1) | +2.1 (+1.5 to +2.7)‡ |
| Needle biopsy: BCS: mastectomy re-excision: no reconstruction | 159 (3) | 14.5 (4.7) | +3.5 (+2.5 to +4.5)‡ |
| Needle biopsy: BCS: mastectomy re-excision: with reconstruction | 78 (1) | 17.8 (4.9) | +6.5 (+5.0 to +7.9)‡ |
| Surgical biopsy: BCS: no re-excision | 211 (3) | 9.2 (4.5) | −1.7 (−2.6 to −0.7)‡ |
| Surgical biopsy: BCS: BCS re-excision | 661 (11) | 11.5 (4.4) | +0.7 (+0.1 to +1.2)† |
| Surgical biopsy: BCS: mastectomy re-excision: no reconstruction | 397 (6) | 12.0 (4.6) | +1.0 (+0.3 to +1.8)‡ |
| Surgical biopsy: BCS: mastectomy re-excision: with reconstruction | 243 (4) | 14.7 (4.9) | +3.7 (+2.8 to +4.6)‡ |
* Pathways were constructed by combining diagnostic biopsy, type of initial surgery, receipt and type of re-excision, and use of reconstruction. Mean is the unadjusted arithmetic mean. ΔTTC data are adjusted for institution and all factors listed in Table 2 except those factors included in the composite surgical pathway. The sign denotes where the reported ΔTTC is longer (+) or shorter (−) than the noted reference group. BCS = breast-conserving surgery.
† P < .05.
‡ P < .001.